Abstract

A 57-year-old male with a history of hypertension presented with shortness of breath, intermittent substernal chest pain, subjective fevers, and a 30-pound weight loss. He was found to have a bladder mass four months prior to presentation, for which he underwent cystoscopy and surgical removal. Pathology demonstrated high-grade superficial plasmacytoid urothelial carcinoma extending into the submucosa but not the muscularis propria. Given the superficial nature of his bladder cancer, a cystectomy was deferred. He was subsequently lost to follow-up care. On arrival, physical exam was notable for tachycardia, tachypnea, and distant heart sounds. An ECG showed an incomplete right bundle branch block and sinus tachycardia. Computed tomography pulmonary angiography revealed a three-cm pericardial effusion. Transthoracic echocardiography confirmed this finding and revealed a mass in the right ventricle (RV) extending into the outflow tract and infiltrating the free wall. The RV was dilated with an estimated RV systolic pressure of 37 mmHg. Pericardiocentesis yielded nearly one liter of serosanguinous fluid with non-diagnostic cytology. Partial median sternotomy with biopsy showed pathologic findings consistent with metastatic urothelial carcinoma, plasmacytoid variant. A PET scan showed increased uptake exclusively in the heart. The oncology team discussed options with the patient including chemotherapy and palliative care. The patient decided to withhold further therapy and went home with hospice care. He died two months later.DiscussionBladder cancer is the fourth most common cancer in men in the United States. Most patients (69%) with metastatic bladder cancer have multiple organs involved; conversely, our patient had a PET scan indicating his disease was localized to the heart. Plasmacytoid urothelial carcinoma is a rare subtype of bladder cancer, and is estimated to make up less than three percent of all invasive bladder carcinomas. At the time of this publication we are aware of only three other reported instances of isolated cardiac metastasis with urothelial bladder origin; none of which were the plasmacytoid variant.ConclusionThis case highlights a previously unreported presentation of plasmacytoid urothelial carcinoma. Clinicians must remember that even superficial cancers can have significant metastatic potential.

Highlights

  • Urothelial cell carcinoma (UCC) with metastasis exclusively to the heart is an extremely rare and atypical presentation of a relatively common malignancy

  • Most patients (69%) with metastatic bladder cancer have multiple organs involved; our patient had a Positron Emission Tomography (PET) scan indicating his disease was localized to the heart

  • Plasmacytoid urothelial carcinoma is a rare subtype of bladder cancer, and is estimated to make up less than three percent of all invasive bladder carcinomas

Read more

Summary

Discussion

Any type of malignancy [8]. Primary tumors most likely to have cardiac metastasis found at autopsy include pleural mesotheliomas (48.4%), melanomas (27.8%), lung adenocarcinomas (21%), and undifferentiated carcinomas (19.5%) [9]. It is estimated to make up less than three percent of all invasive bladder carcinomas [11] It is still a relatively new entity, data far has demonstrated that PUC is an aggressive tumor with extensive local growth and poor prognosis [12]. A review of hematoxylin and eosin (H&E) stained sections of the biopsied primary tumor demonstrated an invasive urothelial carcinoma with discohesive epithelial cells and plasmacytoid features (Figure 5). Whole body PET suggested that the PUC did not persist in his bladder and had not metastasized to any other sites Such findings point to the need for more aggressive interventions and close follow-up for patients with the plasmacytoid variant of UCC, regardless of the degree of tumor infiltration. Competing interests The authors declare that they have no competing interests

Conclusion
Introduction
Findings
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call